CLOVES综合征的遗传学研究进展及相关疾病鉴别
Research Progress on the Genetics of CLOVES Syndrome and the Identification of Related Diseases
DOI: 10.12677/acm.2024.1441349, PDF,   
作者: 赵紫欣, 邝新捷:河南大学人民医院血管瘤外科,河南 郑州;董长宪*:河南省人民医院血管瘤外科,河南 郑州
关键词: PIK3CA/AKT/mTOR通路PIK3CA相关过度生长谱脉管畸形靶向药物PIK3CA/AKT/mTOR Pathway PIK3CA-Related Overgrowth Spectrum Vascular Malformation Targeted Drugs
摘要: 脉管畸形越来越多地被认为是由非遗传性体细胞突变引起的相关综合征。CLOVES综合征是一个相对比较新的临床术语,临床上以先天性脂肪瘤样过度生长(CLO)、脉管畸形(V)、表皮痣(E)和骨骼异常(S)为特征。Sapp等人在2007年首次描述,并由Alomari及其同事在2009年命名为CLOVES,其遗传学特征是由PIK3CA基因嵌合激活突变引起。这是一种进行性疾病,预后是可变的,取决于诊断时的年龄、解剖位置、血管畸形类型和整体健康状况。因此,早期正确的诊断显得很重要。由于其过度生长的侵袭性以及复发和毁容的可能性,手术治疗往往具有挑战性,而PIK3CA突变的确定使得靶向药物的开发成为当前治疗的崭新思路。本文综述了目前所知的这种罕见但具有挑战性的疾病的遗传学研究进展,并介绍其临床特征、鉴别诊断及治疗。
Abstract: Vascular malformations are increasingly being identified as associated syndromes caused by sporadic, unheritable somatic mutations. CLOVES syndrome is a relatively new clinical term, characterized clinically by congenital lipomatous overgrowth (CLO), vascular malformations (V), epidermal nevi (E), and scoliosis/skeletal/spinal anomalies (S). First described by Sapp et al. in 2007 and named as CLOVES by Alomari and his colleagues in 2009, it was genetically characterized by mosaic activating mutation in gene PIK3CA. It is a progressive disease and the prognosis is variable depending on age at diagnosis, anatomic location, type of vascular malformation and overall health status. Therefore, an early and correct diagnosis appears to be important. Surgical treatment is often challenging due to its invasive nature of overgrowth and the possibility of recurrence and disfigurement, and the identification of PIK3CA mutations makes the development of targeted drugs a new idea for current therapies. This review summarizes the progress of the genetics of this rare but challenging disease, and introduces its clinical features, differential diagnosis and treatment.
文章引用:赵紫欣, 邝新捷, 董长宪. CLOVES综合征的遗传学研究进展及相关疾病鉴别[J]. 临床医学进展, 2024, 14(4): 2708-2716. https://doi.org/10.12677/acm.2024.1441349

参考文献

[1] 中华医学会整形外科分会血管瘤和脉管畸形学组. 血管瘤和脉管畸形的诊断及治疗指南(2019版) [J]. 组织工程与重建外科杂志, 2019, 15(5): 277-317.
[2] Tatton-Brown, K. and Weksberg, R. (2013) Molecular Mechanisms of Childhood Overgrowth. American Journal of Medical Genetics. Part C: Seminars in Medical Genetics, 163, 71-75. [Google Scholar] [CrossRef] [PubMed]
[3] Keppler-Noreuil, K.M., Rios, J.J., Parker, V.E.R., et al. (2015) PIK3CA-Related Overgrowth Spectrum (PROS): Diagnostic and Testing Eligibility Criteria, Differential Diagnosis, and Evaluation. American Journal of Medical Genetics Part A, 167, 287-295. [Google Scholar] [CrossRef] [PubMed]
[4] Alomar, S., Khedr, R.E. and Alajlan, S. (2019) CLOVES Syndrome in a Nine-Month-Old Infant. Cureus, 11, e5772. [Google Scholar] [CrossRef] [PubMed]
[5] Bertino, F., Braithwaite, K.A., Hawkins, C.M., et al. (2019) Congenital Limb Overgrowth Syndromes Associated with Vascular Anomalies. Radiographics, 39, 491-515. [Google Scholar] [CrossRef] [PubMed]
[6] Sapp, J.C., Turner, J.T., van de Kamp, J.M., et al. (2007) Newly Delineated Syndrome of Congenital Lipomatous Overgrowth, Vascular Malformations, and Epidermal Nevi (CLOVE Syndrome) in Seven Patients. American Journal of Medical Genetics. Part A, 143A, 2944-2958. [Google Scholar] [CrossRef] [PubMed]
[7] Alomari, A.I. (2009) Characterization of a Distinct Syndrome That Associates Complex Truncal Overgrowth, Vascular, and Acral Anomalies: A Descriptive Study of 18 Cases of CLOVES Syndrome. Clinical Dysmorphology, 18, 1-7. [Google Scholar] [CrossRef
[8] Alomari, A.I., Chaudry, G., Rodesch, G., et al. (2011) Complex Spinal-Paraspinal Fast-Flow Lesions in CLOVES Syndrome: Analysis of Clinical and Imaging Findings in 6 Patients. American Journal of Neuroradiology, 32, 1812-1817. [Google Scholar] [CrossRef
[9] Keppler-Noreuil, K.M., Sapp, J.C., Lindhurst, M.J., et al. (2014) Clinical Delineation and Natural History of the PIK3CA-Related Overgrowth Spectrum. American Journal of Medical Genetics. Part A, 164, 1713-1733. [Google Scholar] [CrossRef] [PubMed]
[10] Lindhurst, M.J., Parker, V.E.R., Payne, F., et al. (2012) Mosaic Overgrowth with Fibroadipose Hyperplasia Is Caused by Somatic Activating Mutations in PIK3CA. Nature Genetics, 44, 928-933. [Google Scholar] [CrossRef] [PubMed]
[11] Mathew, L., George, R., Sudhakar, S., et al. (2020) Clinical Profile of Overgrowth Syndromes Consistent with PROS (PIK3CA-Related Overgrowth Syndromes)—A Case Series. Indian Dermatology Online Journal, 11, 738-746. [Google Scholar] [CrossRef
[12] Yan, W., Zhang, B., Wang, H., et al. (2021) Somatic Frameshift Mutation in PIK3CA Causes CLOVES Syndrome by Provoking PI3K/AKT/mTOR Pathway. Hereditas, 158, Article No. 18. [Google Scholar] [CrossRef] [PubMed]
[13] Wassef, M., Blei, F., Adams, D., et al. (2015) Vascular Anomalies Classification: Recommendations from the International Society for the Study of Vascular Anomalies. Pediatrics, 136, e203-214. [Google Scholar] [CrossRef] [PubMed]
[14] Waldman, A.R., Garzon, M.C. and Morel, K.D. (2022) Epidermal Nevi: What Is New. Dermatologic Clinics, 40, 61-71. [Google Scholar] [CrossRef] [PubMed]
[15] Acosta, S., Torres, V., Paulos, M., et al. (2017) CLOVES Syndrome: Severe Neonatal Presentation. Journal of Clinical and Diagnostic Research, 11, TR01-TR03. [Google Scholar] [CrossRef
[16] Mahajan, V.K., Gupta, M., Chauhan, P., et al. (2019) Cloves Syndrome: A Rare Disorder of Overgrowth with Unusual Features—An Uncommon Phenotype? Indian Dermatology Online Journal, 10, 447-452. [Google Scholar] [CrossRef
[17] St-Pierre, J., Mirakhur, A. and Forbes, N. (2023) Gastrointestinal Manifestations of CLOVES Syndrome. ACG Case Reports Journal, 10, e01050. [Google Scholar] [CrossRef] [PubMed]
[18] 张静, 朱静, 冷洁, 等. PIK3CA相关过度生长谱研究新进展[J]. 重庆医科大学学报, 2023, 48(5): 512-515.
[19] Kinross, K.M., Montgomery, K.G., Mangiafico, S.P., et al. (2015) Ubiquitous Expression of the Pik3ca H1047R Mutation Promotes Hypoglycemia, Hypoinsulinemia, and Organomegaly. The FASEB Journal, 29, 1426-1434. [Google Scholar] [CrossRef] [PubMed]
[20] Vahidnezhad, H., Youssefian, L. and Uitto, J. (2016) Klippel-Trenaunay Syndrome Belongs to the PIK3CA-Related Overgrowth Spectrum (PROS). Experimental Dermatology, 25, 17-19. [Google Scholar] [CrossRef] [PubMed]
[21] Brouillard, P., Schlögel, M.J., Homayun Sepehr, N., et al. (2021) Non-Hotspot PIK3CA Mutations Are More Frequent in CLOVES than in Common or Combined Lymphatic Malformations. Orphanet Journal of Rare Diseases, 16, Article No. 267. [Google Scholar] [CrossRef] [PubMed]
[22] Mirzaa, G., Parry, D.A., Fry, A.E., et al. (2014) De novo CCND2 Mutations Leading to Stabilization of Cyclin D2 Cause Megalencephaly-Polymicrogyria-Polydactyly-Hydrocephalus Syndrome. Nature Genetics, 46, 510-515. [Google Scholar] [CrossRef] [PubMed]
[23] Michel, M.E., Konczyk, D.J., Yeung, K.S., et al. (2018) Causal Somatic Mutations in Urine DNA from Persons with the CLOVES Subgroup of the PIK3CA-Related Overgrowth Spectrum. Clinical Genetics, 93, 1075-1080. [Google Scholar] [CrossRef] [PubMed]
[24] Chang, F., Liu, L., Fang, E., et al. (2017) Molecular Diagnosis of Mosaic Overgrowth Syndromes Using a Custom-Designed Next-Generation Sequencing Panel. The Journal of Molecular Diagnostics, 19, 613-624. [Google Scholar] [CrossRef] [PubMed]
[25] Rehder, C., Bean, L.J.H., Bick, D., et al. (2021) Next-Generation Sequencing for Constitutional Variants in the Clinical Laboratory, 2021 Revision: A Technical Standard of the American College of Medical Genetics and Genomics (ACMG). Genetics in Medicine, 23, 1399-1415. [Google Scholar] [CrossRef] [PubMed]
[26] Martinez-Lopez, A., Blasco-Morente, G., Perez-Lopez, I., et al. (2017) CLOVES Syndrome: Review of a PIK3CA-Related Overgrowth Spectrum (PROS). Clinical Genetics, 91, 14-21. [Google Scholar] [CrossRef] [PubMed]
[27] Accogli, A., Geraldo, A.F., Piccolo, G., et al. (2021) Diagnostic Approach to Macrocephaly in Children. Frontiers in Pediatrics, 9, Article 794069. [Google Scholar] [CrossRef] [PubMed]
[28] Keppler-Noreuil, K.M., Sapp, J.C., Lindhurst, M.J., et al. (2019) Pharmacodynamic Study of Miransertib in Individuals with Proteus Syndrome. American Journal of Human Genetics, 104, 484-491. [Google Scholar] [CrossRef] [PubMed]
[29] Keppler-Noreuil, K.M., Lozier, J.N., Sapp, J.C., et al. (2017) Characterization of Thrombosis in Patients with Proteus Syndrome. American Journal of Medical Genetics. Part A, 173, 2359-2365. [Google Scholar] [CrossRef] [PubMed]
[30] Martinez-Lopez, A., Salvador-Rodriguez, L., Montero-Vilchez, T., et al. (2019) Vascular Malformations Syndromes: An Update. Current Opinion in Pediatrics, 31, 747-753. [Google Scholar] [CrossRef
[31] Pavone, P., Marino, L., Cacciaguerra, G., et al. (2023) Klippel-Trenaunay Syndrome, Segmental/Focal Overgrowth Malformations: A Review. Children (Basel, Switzerland), 10, Article 1421. [Google Scholar] [CrossRef] [PubMed]
[32] Gubala, A., Venkatesh, K., Akhter, M., et al. (2023) High-Output Heart Failure in a Patient with Klippel-Trénaunay Syndrome: A Case Report. Cureus, 15, e38963. [Google Scholar] [CrossRef] [PubMed]
[33] Hu, W., Gong, Y., Ma, J., et al. (2023) Fibro-Adipose Vascular Anomaly: Characteristic Imaging Features on Sonography and Magnetic Resonance Imaging. Vascular and Endovascular Surgery, 57, 106-113. [Google Scholar] [CrossRef] [PubMed]
[34] Hori, Y., Hirose, K., Aramaki-Hattori, N., et al. (2020) Fibro-Adipose Vascular Anomaly (FAVA): Three Case Reports with an Emphasis on the Mammalian target of Rapamycin (mTOR) Pathway. Diagnostic Pathology, 15, Article No. 98. [Google Scholar] [CrossRef] [PubMed]
[35] Escobar, K., Pandher, K. and Jahnke, M.N. (2022) Capillary Malformations. Dermatologic Clinics, 40, 425-433. [Google Scholar] [CrossRef] [PubMed]
[36] Revencu, N., Boon, L.M., Mulliken, J.B., et al. (2008) Parkes Weber Syndrome, Vein of Galen Aneurysmal Malformation, and Other Fast-Flow Vascular Anomalies Are Caused by RASA1 Mutations. Human Mutation, 29, 959-965. [Google Scholar] [CrossRef] [PubMed]
[37] He, B., Sun, M.-S., Liu, J.-W., et al. (2023) Major Limb Amputation in Parkes-Weber Syndrome with Refractory Ulceration: A Case Report and Literature Review. The International Journal of Lower Extremity Wounds, 22, 168-173. [Google Scholar] [CrossRef] [PubMed]
[38] Bichsel, C. and Bischoff, J. (2019) A Somatic Missense Mutation in GNAQ Causes Capillary Malformation. Current Opinion in Hematology, 26, 179-184. [Google Scholar] [CrossRef
[39] Shirley, M.D., Tang, H., Gallione, C.J., et al. (2013) Sturge-Weber Syndrome and Port-Wine Stains Caused by Somatic Mutation in GNAQ. The New England Journal of Medicine, 368, 1971-1979. [Google Scholar] [CrossRef
[40] Fjær, R., Marciniak, K., Sundnes, O., et al. (2021) A Novel Somatic Mutation in GNB2 Provides New Insights to the Pathogenesis of Sturge-Weber Syndrome. Human Molecular Genetics, 30, 1919-1931. [Google Scholar] [CrossRef] [PubMed]
[41] Thorpe, J., Frelin, L.P., McCann, M., et al. (2021) Identification of a Mosaic Activating Mutation in GNA11 in Atypical Sturge-Weber Syndrome. The Journal of Investigative Dermatology, 141, 685-688. [Google Scholar] [CrossRef] [PubMed]
[42] Gill, R.E., Tang, B., Smegal, L., et al. (2021) Quantitative EEG Improves Prediction of Sturge-Weber Syndrome in Infants with Port-Wine Birthmark. Clinical Neurophysiology, 132, 2440-2446. [Google Scholar] [CrossRef] [PubMed]
[43] Yeom, S. and Comi, A.M. (2022) Updates on Sturge-Weber Syndrome. Stroke, 53, 3769-3779. [Google Scholar] [CrossRef
[44] Öztürk Durmaz, E., Demircioğlu, D., Yalınay Dikmen, P., et al. (2022) A Review on Cutaneous and Musculoskeletal Manifestations of CLOVES Syndrome. Clinical, Cosmetic and Investigational Dermatology, 15, 621-630. [Google Scholar] [CrossRef
[45] Van Damme, A., Seront, E., Dekeuleneer, V., et al. (2020) New and Emerging Targeted Therapies for Vascular Malformations. American Journal of Clinical Dermatology, 21, 657-668. [Google Scholar] [CrossRef] [PubMed]
[46] Venot, Q., Blanc, T., Rabia, S.H., et al. (2018) Targeted Therapy in Patients with PIK3CA-Related Overgrowth Syndrome. Nature, 558, 540-546. [Google Scholar] [CrossRef] [PubMed]
[47] López Gutiérrez, J.C., Lizarraga, R., Delgado, C., et al. (2019) Alpelisib Treatment for Genital Vascular Malformation in a Patient with Congenital Lipomatous Overgrowth, Vascular Malformations, Epidermal Nevi, and Spinal/Skeletal Anomalies and/or Scoliosis (CLOVES) Syndrome. Journal of Pediatric and Adolescent Gynecology, 32, 648-650. [Google Scholar] [CrossRef] [PubMed]
[48] Garreta Fontelles, G., Pardo Pastor, J. and Grande Moreillo, C. (2022) Alpelisib to Treat CLOVES Syndrome, a Member of the PIK3CA-Related Overgrowth Syndrome Spectrum. British Journal of Clinical Pharmacology, 88, 3891-3895. [Google Scholar] [CrossRef] [PubMed]
[49] Forde, K., Resta, N., Ranieri, C., et al. (2021) Clinical Experience with the AKT1 Inhibitor Miransertib in Two Children with PIK3CA-Related Overgrowth Syndrome. Orphanet Journal of Rare Diseases, 16, Article No. 109. [Google Scholar] [CrossRef] [PubMed]